Search Result

Results for "

Lymphoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (19) BCL6 (11) MALT1 (11) 5-HT Receptor (1) ADC Antibody (7) ADC Payload (8) Adenosine Deaminase (3) Adenosine Receptor (1) Akt (7) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (10) Antibody-Drug Conjugates (ADCs) (5) Antifolate (3) Apoptosis (101) Arp2/3 Complex (1) ATM/ATR (2) Aurora Kinase (2) Autophagy (18) Bacterial (8) Bcl-2 Family (25) Bcr-Abl (1) Biochemical Assay Reagents (3) Btk (25) c-Fms (1) c-Myc (3) C-type Lectin-like Receptors (CTLRs) (1) Calcium Channel (1) Casein Kinase (8) Caspase (6) CCR (2) CD19 (6) CD20 (10) CD22 (6) CD28 (2) CD3 (2) CD47 (4) CD73 (1) CDK (16) COX (2) CRM1 (2) CXCR (5) Cytochrome P450 (6) Deubiquitinase (1) Dihydroorotate Dehydrogenase (1) DNA Alkylator/Crosslinker (5) DNA Methyltransferase (2) DNA/RNA Synthesis (17) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (2) Drug Metabolite (4) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (19) E3 Ligase Ligand-Linker Conjugates (3) EGFR (5) Endogenous Metabolite (4) Epigenetic Reader Domain (3) ERK (2) FAK (1) Fc Receptor (FcR) (1) FLT3 (4) Free Fatty Acid Receptor (2) Fungal (10) Glucocorticoid Receptor (1) Glutaminase (1) HDAC (13) Herbicide (1) Histone Acetyltransferase (3) Histone Demethylase (1) Histone Methyltransferase (31) HIV (9) HSP (1) HSV (1) IAP (1) IGF-1R (2) IKK (1) Influenza Virus (2) Insulin Receptor (1) Integrin (2) Interleukin Related (3) IRAK (15) Isotope-Labeled Compounds (16) Itk (1) JAK (3) JNK (2) Lactate Dehydrogenase (1) LAG-3 (4) Ligands for E3 Ligase (9) Ligands for Target Protein for PROTAC (3) Liposome (3) MAP3K (1) MAP4K (1) MDM-2/p53 (8) MetAP (1) Methionine Adenosyltransferase (MAT) (1) MicroRNA (2) Microtubule/Tubulin (10) Mitochondrial Metabolism (2) Mitosis (2) MMP (3) Molecular Glues (20) Monoamine Oxidase (1) Monocarboxylate Transporter (1) mRNA (2) mTOR (1) MyD88 (2) N-myristoyltransferase (2) NAMPT (1) Necroptosis (1) NEKs (1) NF-κB (9) Notch (3) Nucleoside Antimetabolite/Analog (4) P-glycoprotein (1) Parasite (6) PARP (2) PD-1/PD-L1 (15) Phosphatase (2) Phospholipase (1) PI3K (20) Pim (1) PPAR (1) PROTACs (21) Proteasome (2) PTEN (2) Pyroptosis (1) Radionuclide-Drug Conjugates (RDCs) (2) RAR/RXR (5) Ras (2) Reactive Oxygen Species (ROS) (5) Reference Standards (17) ROR (1) ROS Kinase (3) RSV (1) SARS-CoV (2) Ser/Thr Protease (1) SHMT (1) Sialyltransferase (1) SphK (1) Src (2) STAT (12) STING (1) Survivin (2) Target Protein Ligand-Linker Conjugates (1) Tie (1) Tim3 (1) TNF Receptor (15) Topoisomerase (9) Transmembrane Glycoprotein (6) Trk Receptor (1) Tyrosinase (2) VEGFR (3) WDR5 (1) Wnt (4) β-catenin (6)
By Research Areas:	Cancer (437) Cardiovascular Disease (11) Endocrinology (4) Infection (35) Inflammation/Immunology (78) Metabolic Disease (6) Neurological Disease (9)
Click Chemistry:	PROTAC Synthesis (2) Alkynes (1)
Oligonucleotides:	Nucleotides and their Analogs (1) Nucleosides and their Analogs (1) C (1) Pegylated Lipids (1) U (1) mRNA (2) Phospholipids (1) Antisense Oligonucleotides (2)

466

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

ALK-IN-28	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK) .

Urelumab	TNF Receptor	Inflammation/Immunology Cancer
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

DM-01	Histone Methyltransferase	Cancer
DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors .

Tazemetostat de(methyl morpholine)-COOH	Ligands for Target Protein for PROTAC	Cancer
Tazemetostat de(methyl morpholine)-COOH (compound 7) is a ligand for the PROTAC target protein EZH2, which can be used to synthesis of EZH2 degraders (PROTACs). EZH2 degraders have potent cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphoma .

SGR-1505	MALT1	Inflammation/Immunology Cancer
SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas .

Valemetostat 4 Publications Verification DS-3201	Histone Methyltransferase	Cancer
Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma .

2-Phenylbutanoic acid	Biochemical Assay Reagents HIV	Infection Cancer
2-Phenylbutanoic acid is a monocarboxylic acid. 2-Phenylbutanoic acid interacts with proteins. 2-Phenylbutanoic acid is used in the study of malignant lymphoma and HIV virus-related diseases .

Zuberitamab HS006	CD20	Cancer
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

Dezapelisib INCB040093	PI3K	Cancer
Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas .

Asaretoclax	Bcl-2 Family	Cancer
Asaretoclax is a potent *B-cell lymphoma* 2 (Bcl-2)** inhibitor. Asaretoclax has the potential for the research of cancer .

Tenacigenin B	Aurora Kinase	Cancer
Tenacigenin B is a steroid that can be isolated from the genus Alocasia. Tenacigenin B has anti-tumor effects on lymphoma via regulation of Aurora-A .

Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH	Histone Methyltransferase Target Protein Ligand-Linker Conjugates	Cancer
Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH (Compound 21b) incorporates a ligand for EZH2, and a PROTAC linker, which recruit E3 ligases. Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH (Compound 21b) can be used for the research of lymphoma .

ALK kinase inhibitor-1	Anaplastic lymphoma kinase (ALK)	Cancer
ALK kinase inhibitor-1 is an *anaplastic lymphoma* kinase (ALK)** inhibitor extracted from patent US20130261106A1 compound I-202 .

BTK-IN-44	Btk	Cancer
BTK-IN-44 (Compound 10) is a potent noncovalent inhibitor of Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 24.7 nM. BTK-IN-44 interferes with signaling pathways of B cell malignancies, showing antitumor effects in lymphoma cells. BTK-IN-44 is promising for research of B cell malignancies (such as lymphoma) .

CDK-TCIP2	CDK BCL6	Cancer
DK-TCIP2, linking inhibitor of CDK9 SNS-032 (HY-10008) with ligands of BCL6 BI-3812 (HY-111381), is a anticancer agent. DK-TCIP2 shows anticancer activity in vivo and in vitro and can be used for study of lymphoma cancer .

PI3K-IN-36	PI3K	Cancer
PI3K-IN-36 (compound A36) is a potent PI3K inhibitor. PI3K-IN-36 can be used in research of follicular lymphoma (FL) .

DCE_42	Histone Methyltransferase	Cancer
DCE_42 is a potent EZH2 inhibitor with an IC₅₀ value of 22.6 µM. DCE_42 inhibits cell proliferation and has the potential for the research of lymphoma .

PSI TFA Proteasome Inhibitor 1 TFA; Z-Ile-Glu(OtBu)-Ala-Leu-CHO TFA	Proteasome	Infection Cancer
PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

PSI Proteasome Inhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO	Proteasome	Infection Cancer
PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HLX26	LAG-3	Cancer
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .

Epratuzumab Antibody hLL 2	CD22	Inflammation/Immunology Cancer
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .

ARV-393	PROTACs BCL6	Cancer
ARV-393 is a potent and orally active BCL6 PROTAC degrader. ARV-393 induces ubiquitination of BCL6 and its subsequent degradation by the proteasome. ARV-393 has the potential for the research of advanced non-hodgkin lymphoma .

Tubulin polymerization-IN-34	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-34 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line .

Tubulin polymerization-IN-35	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-35 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line .

Ripertamab SCT400	CD20	Cancer
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .

Bexarotene-d4 LGD1069 d₄	RAR/RXR Autophagy	Cancer
Bexarotene-d₄ is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma .

Sonrotoclax BGB 11417	Bcl-2 Family	Cancer
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines .

iHSP110-33	HSP STAT	Cancer
iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

E3 Ligase Ligand-linker Conjugate 170	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 170 (Compound I) exhibits anti-proliferative activity in non-Hodgkin's lymphoma cell SU-DHL-4 with IC₅₀ < 0.2 μM. E3 Ligase Ligand-linker Conjugate 170 is the conjugate composed of an E3 ligase ligand and a linker that can be used for PROTAC synthesis .

SHMT-IN-2	SHMT	Endocrinology Cancer
SHMT-IN-2 is a stereo specific inhibitor of human SHMT1/2 with IC₅₀ values of 13 nM and 66 nM for SHMT1 and SHMT2, respectively. SHMT-IN-2 can block the growth of many human cancer cells, and has sensitivity for B-cell lymphomas .

Tubulin polymerization-IN-32	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-32 is a tubulin polymerization inhibitor. Tubulin polymerization-IN-32 inhibits cancer cell proliferation. Tubulin polymerization-IN-32 can be used in the research of cancers like lymphomas .

BMS-986238	PD-1/PD-L1	Cancer
BMS-986238, a second-generation macrocyclic peptide, is a potent PD-L1 inhibitor. BMS-986238 has the potential for the study of solid tumours and lymphomas (cancer of the lymphatic system) .

EBU-141	Sialyltransferase	Cancer
EBU-141 is a human monoclonal antibody (mAb) targeting CD75/ST6GAL1. EBU-141 can be used in B-cell lymphoma and multiple myeloma research .

Z-VRPR-FMK	MALT1	Cancer
Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .

BCOR(498-514), biotinylated	BCL6	Cancer
BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an K_D value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells .

Apoptosis inducer 11	Apoptosis	Cancer
Apoptosis inducer 11 (compound 3u) induces apoptosis through the mitochondrial pathway. Apoptosis inducer 11 induces a block in G2/M, a strong decrease in S phase in non-Hodgkin lymphoma cell lines .

SEA-TGT	Transmembrane Glycoprotein	Cancer
SEA-TGT is a human monoclonal antibody (mAb) targeting TIGIT. SEA-TGT enhances binding to the activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT can be used in advanced solid tumors and Lymphoma research .

Brentuximab	ADC Antibody TNF Receptor	Cancer
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC₅₀ of 10 nM against human CD30+ cancer cells .

MMRi64	MDM-2/p53 Apoptosis	Cancer
MMRi64 disrupts Mdm2-MdmX interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces p53 accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research .

Anti-inflammatory agent 45	Apoptosis	Cancer
Anti-inflammatory agent 45 (compound 2v) is an anticancer agent with direct inhibitory effects on the growth of different blood cancers including leukemia, lymphoma and myeloma cell lines. Anti-inflammatory agent 45 induces apoptosis and inhibits NO production in HL60 leukemia cells (IC₅₀=14.7 μM) .

BTK-IN-27	Btk	Inflammation/Immunology Cancer
BTK-IN-27 (example 8) is a BTK inhibitor (IC₅₀: 0.2 nM). BTK-IN-27 shows anti-proliferative activity in TMD8 cells (IC₅₀: < 5 nM). BTK-IN-27 can be used for research of cancer, lymphoma, leukemia and immunological diseases .

BCL6-IN-9	Bcl-2 Family	Cancer
BCL6-IN-9 (compound 1) is a potent *B-cell lymphoma* 6 protein (BCL6) inhibitor, with an IC₅₀** of 3.9 nM. BCL6-IN-9 can be used for the research of cancer .

BLX-301	CD20	Inflammation/Immunology Cancer
BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .

BTK-IN-41	Btk	Cancer
BTK-IN-41 (Compound 47) is the inhibitor for BTK with an IC₅₀ of 5.4 nM. BTK-IN-41 inhibits the diffuse large B cell lymphoma cell TDM-8 with IC₅₀ of 13.8 nM .

Cat. No.	Product Name

HY-L171

Anti-Hematopathy Compound Library

3,497 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 3,497 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

HY-L079

Anti-Blood Cancer Compound Library

3,455 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 3,455 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L075

Anti-Lung Cancer Compound Library

2,352 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 2,352 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-16700G

PNU-159682 (GMP)	Fluorescent Dye
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.

Cat. No.	Product Name	Type

HY-140739

DSPE-PEG2000-Maleimide

2 Publications Verification

Drug Delivery

DSPE-PEG2000-Maleimide is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration .

HY-40020

1-Boc-3-piperidone	Biochemical Assay Reagents
1-Boc-3-piperidone is a Boc-protected piperidone derivative. 1-Boc-3-piperidone is an important intermediate in organic synthesis. 1-Boc-3-piperidone can be used to study compounds related to inflammatory skin diseases (such as atopic dermatitis), lymphoma, and other diseases .

HY-16700G

PNU-159682 (GMP)	Biochemical Assay Reagents
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.

HY-151506

Phospholipid PL1	Drug Delivery
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity .

Cat. No.	Product Name	Target	Research Area

HY-P1258

PSI Proteasome Inhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO	Proteasome	Infection Cancer
PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-172320

BMS-986238	PD-1/PD-L1	Cancer
BMS-986238, a second-generation macrocyclic peptide, is a potent PD-L1 inhibitor. BMS-986238 has the potential for the study of solid tumours and lymphomas (cancer of the lymphatic system) .

HY-P1407

Z-VRPR-FMK TFA VRPR	MALT1 Influenza Virus	Infection Cancer
Z-VRPR-FMK (TFA) (VRPR), a tetrapeptide, is a selective and irreversible MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor. Z-VRPR-FMK (TFA) can protect against influenza A virus (IAV) infection .

HY-P1258A

PSI TFA Proteasome Inhibitor 1 TFA; Z-Ile-Glu(OtBu)-Ala-Leu-CHO TFA	Proteasome	Infection Cancer
PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-P10566

BCOR(498-514), biotinylated	BCL6	Cancer
BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an K_D value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells .

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of *B cell lymphoma* 6 (BCL6), with an IC₅₀** of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-100866

F1324	Bcl-2 Family	Cancer
F1324 is a potent, high affinity peptidic inhibitor of *B cell lymphoma* 6 (BCL6) with an IC₅₀** of 1 nM. F1324 exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of *B cell lymphoma* 6 (BCL6), with an IC₅₀** of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-P3602

C3 Peptide P16	Peptides	Cancer
C3 Peptide P16, is a 16 amino acid synthetic peptide derived from human C3d, a fragment generated in trypsin-cleaved C3. C3 Peptide P16 enhances in vitro phosphorylation of pp105 and pp100, a cellular component presenting in the human B lymphoma cells .

HY-169684

Vaccarin C	Fungal	Infection Cancer
Vaccarin C (Compound VIII) is a cycloheptapeptide with good antifungal activity against pathogenic fungi and dermatophytes M. audouinii and T. mentagrophytes with MIC values of 6 µg/mL. Vaccarin C also has high cytotoxicity against Dalton's lymphoma ascites (DLA) and Ehrlich's ascites carcinoma (EAC) cell lines with IC₅₀ values of 3.35 and 5.72 μM, respectively .

HY-P5472

Tumour-associated MUC1 epitope	Transmembrane Glycoprotein	Others
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)

Cat. No.	Product Name	Target	Research Area

HY-P99055

Urelumab	TNF Receptor	Inflammation/Immunology Cancer
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

HY-P99501

Zuberitamab HS006	CD20	Cancer
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

HY-P99619

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .

HY-P99289

Epratuzumab Antibody hLL 2	CD22	Inflammation/Immunology Cancer
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .

HY-P99952

Ripertamab SCT400	CD20	Cancer
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-P99851

Detumomab SPECIFID	Inhibitory Antibodies	Cancer
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).

HY-P991605

HLX26	LAG-3	Cancer
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .

HY-P991369

EBU-141	Sialyltransferase	Cancer
EBU-141 is a human monoclonal antibody (mAb) targeting CD75/ST6GAL1. EBU-141 can be used in B-cell lymphoma and multiple myeloma research .

HY-P991394

SEA-TGT	Transmembrane Glycoprotein	Cancer
SEA-TGT is a human monoclonal antibody (mAb) targeting TIGIT. SEA-TGT enhances binding to the activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT can be used in advanced solid tumors and Lymphoma research .

HY-P99151

Brentuximab	ADC Antibody TNF Receptor	Cancer
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC₅₀ of 10 nM against human CD30+ cancer cells .

HY-P991548

BLX-301	CD20	Inflammation/Immunology Cancer
BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .

HY-P99056

Utomilumab PF 05082566	TNF Receptor	Inflammation/Immunology Cancer
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 ⁺ non-Hodgkin lymphomas .

HY-P99273

Vorsetuzumab	TNF Receptor	Cancer
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .

HY-P99369

Lacutamab IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)	Inhibitory Antibodies	Cancer
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma .

HY-P991345

MEDI-0680 AMP-514	PD-1/PD-L1	Cancer
MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-132253

Polatuzumab vedotin	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-P991397

Sym023	Tim3	Cancer
Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .

HY-P991556

TQB2916	TNF Receptor	Cancer
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .

HY-P991544

TRS-005 Antibody	CD20 ADC Antibody	Cancer
TRS-005 Antibody is an antibody that targets CD20-positive tumor cells. TRS-005 Antibody can be used in the synthesis of antibody-drug conjugates (ADCs). TRS-005 Antibody can be used in the study of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) .

HY-P99224

Veltuzumab IMMU-106; hA20	Integrin	Cancer
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC₅₀ value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .

HY-P99266

Zanolimumab Anti-Human CD4 Recombinant Antibody	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .

HY-P99922

Encelimab	LAG-3	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .

HY-P99338

Tisagenlecleucel CTL019	CD19	Inflammation/Immunology Cancer
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .

HY-P99233

Camidanlumab HuMax-TAC	ADC Antibody Transmembrane Glycoprotein Interleukin Related	Cancer
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991176

RG-6333 RO7443904	CD19 CD28	Cancer
RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) .

HY-P99293

Galiximab IDEC 114; Anti-Human CD80 Recombinant Antibody	CD28 Apoptosis	Cancer
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-P99230

Pinatuzumab	Integrin CD22	Cancer
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99656

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

HY-P99264A

Inotuzumab (powder) Humanized Anti-CD22 Recombinant Antibody (powder)	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma . x

HY-P991561

AO-176	CD47	Cancer
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .

HY-P991555

XmAb5485	TNF Receptor Apoptosis	Cancer
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-141599

Camidanlumab tesirine ADCT 301	Antibody-Drug Conjugates (ADCs) Interleukin Related	Cancer
Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-P99024

Glofitamab RO7082859	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .

HY-P99033

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P99669

Iratumumab MDX-060	TNF Receptor	Cancer
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .

HY-P99711

Loncastuximab RB4v1.2	CD19 ADC Antibody	Cancer
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349) .

HY-P9910

Obinutuzumab GA101; Anti-Human CD20 type II, Humanized Antibody	CD20	Cancer
Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

HY-P99464

Bectumomab IMMU-LL 2	CD22	Cancer
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P991512

SGN-30	Apoptosis	Cancer
SGN-30 is a chimeric antibody derived from a mouse antihuman CD30 antibody, AC10, with the variable regions of AC10 and human α 1 heavy chain and κ light chain constant regions. SGN-30 induces apoptosis and cell-cycle arrest in cancer cells. SGN-30 can be used for the study of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99914

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor	Inflammation/Immunology
Emfizatamab is an anti-CD19/CD3E/TNFRSF9/PD-L1 monoclonal antibody .

HY-P991303

TQB-2223 Sym022; S 95017	LAG-3	Cancer
TQB-2223 is a human monoclonal antibody (mAb) targeting CD223/LAG3. TQB-2223 can be used in the study of Hodgkin lymphoma .

Species:	Human (13) Mouse (4)
Tag:	His (10) Tag Free (5) Strep (1) Avi (1) GST (1) Fc (1) B2M (1)
Source:	HEK293 (2) Sf9 insect cells (2) E. coli (13)

Cat. No.	Compare	Product Name	Species	Source

HY-P72102

	BCL6 Protein, Human (GST) B cell CLL/Lymphoma 6; B cell Lymphoma 6 protein; B-cell Lymphoma 5 protein; B-cell Lymphoma 6 protein; BCL 5; Bcl 6; BCL-5; BCL-6; BCL5; BCL6; BCL6_HUMAN; BCL6A; Protein LAZ-3; ZBTB 27; ZBTB27; Zinc finger protein 51; zinc finger transcription factor BCL6S; ZNF 51; ZNF51	Human	E. coli
	BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human (GST) is the recombinant human-derived BCL6 protein, expressed by E. coli , with N-GST labeled tag.

HY-P7537

	BCL2 Protein, Human (His) rHuApoptosis Regulator Bcl-2, His; B-cell Lymphoma 2; Apoptosis Regulator Bcl-2	Human	E. coli
	BCL2 Protein regulates the mitochondrial membrane permeability, and inhibits the caspase activity, thereby suppressing the apoptosis in various cell types. BCL2 Protein interacts with BECN1 and AMBRA1, and inhibits the autophagy. BCL2 Protein, Human (His) is the human-derived resombinant BCL2 Protein that is expressed in in E. coli with a His tag at the C-terminus.

HY-P74530

	TCL1A Protein, Human (His) T-cell leukemia/Lymphoma protein 1A; Oncogene TCL-1; TCL1A; TCL1	Human	E. coli
	TCL1A protein plays a crucial role in cell signaling by actively enhancing the phosphorylation and activation of AKT1, AKT2, and AKT3 while promoting the nuclear translocation of AKT1. Additionally, it aids cell proliferation, stabilizes mitochondrial membrane potential, and promotes cell survival. TCL1A Protein, Human (His) is the recombinant human-derived TCL1A protein, expressed by E. coli , with N-His labeled tag.

HY-P702575

	BCL6 Protein, Human B cell CLL/Lymphoma 6; B cell Lymphoma 6 protein; B-cell Lymphoma 5 protein; B-cell Lymphoma 6 protein; BCL 5; Bcl 6; BCL-5; BCL-6; BCL5; BCL6; BCL6_HUMAN; BCL6A; Protein LAZ-3; ZBTB 27; ZBTB27; Zinc finger protein 51; zinc finger transcription factor BCL6S; ZNF 51; ZNF51	Human	E. coli
	BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human is the recombinant human-derived BCL6 protein, expressed by E. coli , with tag free.

HY-P702715

	ALK Protein, Human (L1196M, Biotinylated, sf9, Avi) ALK; anaplastic Lymphoma receptor tyrosine kinase; anaplastic Lymphoma kinase (Ki 1); ALK tyrosine kinase receptor; CD246; CD246 antigen; mutant anaplastic Lymphoma kinase; NBLST3	Human	Sf9 insect cells
	ALK Protein, Human (L1196M, Biotinylated, sf9, Avi) is the recombinant human-derived ALK, expressed by Sf9 insect cells , with Avi labeled tag.

HY-P703827

	ALK Protein, Mouse (HEK293, hFc) ALK tyrosine kinase receptor; Anaplastic Lymphoma kinase; Alk;	Mouse	HEK293
	ALK Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived ALK protein, expressed by HEK293, with C-hFc tag.

HY-P701366

	CDK6-CCND1 Heterodimer Protein, Human (sf9) CDK6; CCND1; Cyclin-dependent kinase 6; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE; G1/S-specific cyclin-D1; B-cell Lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	Human	Sf9 insect cells
	The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND1 Heterodimer protein, expressed by sf9 insect cells , with tag free.

HY-P701951

	PARP14 Protein, Human PARP14; Protein mono-ADP-ribosyltransferase PARP14; ADP-ribosyltransferase diphtheria toxin-like 8; ARTD8; B aggressive Lymphoma protein 2; Poly [ADP-ribose] polymerase 14; PARP-14	Human	E. coli
	The PARP14 protein is an ADP-ribosyltransferase that uniquely mono-ADP-ribosylates glutamic acid residues on target proteins such as STAT1 and STAT6, unlike PARP1 and PARP2. It catalyzes STAT1 mono-ADP ribosylation at “Glu-657” and “Glu-705”, reduces STAT1 phosphorylation and inhibits the production of pro-inflammatory cytokines in macrophages following IFNG stimulation. PARP14 Protein, Human is the recombinant human-derived PARP14 protein, expressed by E. coli , with tag free.

HY-P702072

	DTX3L Protein, Human DTX3L; E3 ubiquitin-protein ligase DTX3L; B-Lymphoma- and BAL-associated protein; Protein deltex-3-like; RING-type E3 ubiquitin transferase DTX3L; Rhysin-2; Rhysin2	Human	E. coli
	DTX3L protein is an E3 ubiquitin protein ligase that cooperates with PARP9 in DNA damage repair and antiviral responses. It monoubiquitylates histones (H2A, H2B, H3, H4), especially “Lys-91” of H4, possibly signaling additional modifications. DTX3L Protein, Human is the recombinant human-derived DTX3L protein, expressed by E. coli , with tag free.

HY-P701953

	PARP15 Protein, Human (His) PARP15; Protein mono-ADP-ribosyltransferase PARP15; ADP-ribosyltransferase diphtheria toxin-like 7; ARTD7; B-aggressive Lymphoma protein 3; Poly [ADP-ribose] polymerase 15; PARP-15	Human	E. coli
	PARP15 protein, acting as a mono-ADP-ribosyltransferase, facilitates the mono-ADP-ribosylation of target proteins. It also functions as a transcriptional negative regulator, impacting cellular processes and gene expression. PARP15 Protein, Human (His) is the recombinant human-derived PARP15 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P702073

	DTX3L Protein, Human (His) DTX3L; E3 ubiquitin-protein ligase DTX3L; B-Lymphoma- and BAL-associated protein; Protein deltex-3-like; RING-type E3 ubiquitin transferase DTX3L; Rhysin-2; Rhysin2	Human	E. coli
	DTX3L protein is an E3 ubiquitin protein ligase that cooperates with PARP9 in DNA damage repair and antiviral responses. It monoubiquitylates histones (H2A, H2B, H3, H4), especially “Lys-91” of H4, possibly signaling additional modifications. DTX3L Protein, Human (His) is the recombinant human-derived DTX3L protein, expressed by E. coli , with N-6*His labeled tag.

HY-P704020

	GZMA/Granzyme A Protein, Mouse (His) Gzma; Ctla-3; Ctla3; Mtsp-1; Granzyme A; EC 3.4.21.78; Autocrine thymic Lymphoma granzyme-like serine protease; CTLA-3; Fragmentin-1; T cell-specific serine protease 1; TSP-1	Mouse	E. coli
	GZMA/granzyme A is enriched in cytotoxic T cells and natural killer cells and can induce caspase-independent pyroptosis after delivery to target cells. With substrate specificity for lysine or arginine residues, GZMA cleaves APEX1 and the nucleosome assembly protein SET, thereby disrupting their activity. GZMA/Granzyme A Protein, Mouse (His) is the recombinant mouse-derived GZMA/Granzyme A protein, expressed by E. coli , with C-6*His labeled tag.

HY-P704224

	CXCR5/CD185 Protein-VLP, Human (HEK293) BLR1; L CD185; L MDR15; LC-X-C chemokine receptor type 5; LBurkitt Lymphoma receptor 1; LMonocyte-derived receptor 15 (MDR-15)	Human	HEK293
	CXCR5/CD185 Protein-VLP, Human (HEK293) is the recombinant human-derived CXCR5/CD185 protein, expressed by HEK293, with C-His tag.

HY-P701952

	PARP14 Protein, Human (His, StrepⅡ) PARP14; Protein mono-ADP-ribosyltransferase PARP14; ADP-ribosyltransferase diphtheria toxin-like 8; ARTD8; B aggressive Lymphoma protein 2; Poly [ADP-ribose] polymerase 14; PARP-14	Human	E. coli
	The PARP14 protein is an ADP-ribosyltransferase that uniquely mono-ADP-ribosylates glutamic acid residues on target proteins such as STAT1 and STAT6, unlike PARP1 and PARP2. It catalyzes STAT1 mono-ADP ribosylation at “Glu-657” and “Glu-705”, reduces STAT1 phosphorylation and inhibits the production of pro-inflammatory cytokines in macrophages following IFNG stimulation. PARP14 Protein, Human (His, Strep) is the recombinant human-derived PARP14 protein, expressed by E. coli , with N-Strep, N-8*His labeled tag.

HY-P72220

	GZMA/Granzyme A Protein, Mouse (His-B2M) Gzma; Ctla-3; Ctla3; Mtsp-1; Granzyme A; EC 3.4.21.78; Autocrine thymic Lymphoma granzyme-like serine protease; CTLA-3; Fragmentin-1; T cell-specific serine protease 1; TSP-1	Mouse	E. coli
	GZMA/granzyme A is enriched in cytotoxic T cells and natural killer cells and can induce caspase-independent pyroptosis after delivery to target cells. With substrate specificity for lysine or arginine residues, GZMA cleaves APEX1 and the nucleosome assembly protein SET, thereby disrupting their activity. GZMA/Granzyme A Protein, Mouse (His-B2M) is the recombinant mouse-derived GZMA/Granzyme A protein, expressed by E. coli , with N-6*His, N-B2M labeled tag.

HY-P72119

	CCND1 Protein, Human (His) AI327039; B cell leukemia 1; B-cell Lymphoma 1 protein; BCL 1; BCL-1; BCL-1 oncogene; BCL1; BCL1 oncogene; ccnd1; CCND1/FSTL3 fusion gene; CCND1/FSTL3 fusion gene; included; CCND1/IGHG1 fusion gene; CCND1/IGLC1 fusion gene; CCND1_HUMAN; cD1; Cyl 1; D11S287E; G1/S specific cyclin D1; G1/S-specific cyclin-D1; PRAD1; PRAD1 oncogene; U21B31	Human	E. coli
	The CCND1 protein is a regulatory component of the cyclin D1-CDK4 complex that coordinates phosphorylation and RB family inhibition to regulate the G(1)/S transition. This promotes the dissociation of E2F from the RB/E2F complex and promotes the transcription of E2F target genes critical for G(1) phase progression. CCND1 Protein, Human (His) is the recombinant human-derived CCND1 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P700219AF

	Animal-Free SDF-1 alpha/CXCL12 Protein, Mouse (His) 1 Publications Verification CXCL12; Stromal cell-derived factor 1; SDF-1; 12-O-tetradecanoylphorbol 13-acetate repressed protein 1; TPAR1; C-X-C motif chemokine 12; Pre-B cell growth-stimulating factor; PBSF; Thymic Lymphoma cell-stimulating factor; TLSF; Sdf1	Mouse	E. coli
	The SDF-1 α/CXCL12 protein acts as a chemoattractant with specific activity on T lymphocytes and monocytes (excluding neutrophils).It activates the CXC chemokine receptor CXCR4, inducing a rapid and transient rise in intracellular calcium ions and promoting chemotaxis.Animal-Free SDF-1 alpha/CXCL12 Protein, Mouse (His) is the recombinant mouse-derived animal-FreeSDF-1 alpha/CXCL12 protein, expressed by E.coli , with C-His labeled tag.This product is for cell culture use only.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81596

	MALT1 Antibody (YA1341) MALT1; MLT; Mucosa-associated lymphoid tissue Lymphoma translocation protein 1; MALT Lymphoma-associated translocation; Paracaspase	WB, ICC/IF, FC	Human
	MALT1 Antibody (YA1341) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1341), targeting MALT1, with a predicted molecular weight of 92 kDa (observed band size: 92 kDa). MALT1 Antibody (YA1341) can be used for WB, ICC/IF, FC experiment in human background.

HY-P81443

	Bcl10 Antibody (YA1188) BCL10; CIPER; CLAP; B-cell Lymphoma/leukemia 10; B-cell CLL/Lymphoma 10; Bcl-10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; hCLAP; CED-3/ICH-1 prodomain homologous E10-like regulator; CIPER; Cellular homolog	IHC-P	Human
	Bcl10 Antibody (YA1188) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1188), targeting Bcl10. Bcl10 Antibody (YA1188) can be used for IHC-P experiment in human background.

HY-P81536

	Bcl6 Antibody (YA1281) BCL6; BCL5; LAZ3; ZBTB27; ZNF51; B-cell Lymphoma 6 protein; BCL-6; B-cell Lymphoma 5 protein; BCL-5; Protein LAZ-3; Zinc finger and BTB domain-containing protein 27; Zinc finger protein 51	IHC-P	Human
	Bcl6 Antibody (YA1281) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1281), targeting Bcl6. Bcl6 Antibody (YA1281) can be used for IHC-P experiment in human background.

HY-P85051

	Bcl-10 Antibody (YA4743) BCL10; CIPER; CLAP; B-cell Lymphoma/leukemia 10; B-cell CLL/Lymphoma 10; Bcl-10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; hCLAP; CED-3/ICH-1 prodomain homologous E10-like regulator; CIPER; Cellular homolog	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse
	Bcl-10 Antibody (YA4743) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Bcl-10. It can be applicated for WB, IHC-P, ICC/IF, FC, ELISA assays, in the background of human, mouse.

HY-P85808

	Bcl-6 Antibody (YA5500) BCL6; BCL5; LAZ3; ZBTB27; ZNF51; B-cell Lymphoma 6 protein; BCL-6; B-cell Lymphoma 5 protein; BCL-5; Protein LAZ-3; Zinc finger and BTB domain-containing protein 27; Zinc finger protein 51	WB, ICC/IF, ELISA	Human, Mouse,
	Bcl-6 Antibody (YA5500) is a mouse-derived and non-conjugated IgG3 monoclonal antibody, targeting to Bcl-6. It can be applicated for WB, ICC/IF, ELISA assays, in the background of human, mouse.

HY-P85928

	TCL1 Antibody (YA5620) Anti TCL1A; Lymphoma/leukemia, T-cell; Oncogene TCL-1; Oncogene TCL1; P14 TCL1; P14 TCL1 protein; Protein p14 TCL1; T cell leukemia 1; T cell Lymphoma 1; T cell Lymphoma 1A; T-cell leukemia/Lymphoma 1A; T-cell leukemia/Lymphoma protein 1A; TCL 1 protein; TCL1; TCL1 oncogene; TCL1 PEN; Tcl1a; TCL1A; TCL1A_HUMAN	IHC-P, WB, ICC/IF, ELISA	Human
	TCL1 Antibody (YA5620) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to TCL1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.

HY-P85114

	Cyclin D1 Antibody (YA4806) CCND1; BCL1; PRAD1; G1/S-specific cyclin-D1; B-cell Lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	WB, ELISA	Human
	Cyclin D1 Antibody (YA4806) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Cyclin D1. It can be applicated for WB, ELISA assays, in the background of human.

HY-P86563

	Cyclin D1 Antibody (YA6255) CCND1; BCL1; PRAD1; G1/S-specific cyclin-D1; B-cell Lymphoma 1 protein; BCL-1; BCL-1 oncogene; PRAD1 oncogene	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Cyclin D1 Antibody (YA6255) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cyclin D1. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.

HY-P86369

	ALK Antibody (YA6061) ALK; ALK tyrosine kinase receptor; Anaplastic Lymphoma kinase; CD antigen CD246	WB, IHC-P, ICC/IF, IP, ELISA	Human
	ALK Antibody (YA6061) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ALK. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human.

HY-P81959

	*T Cell Leukemia/Lymphoma* Protein 1A Antibody (YA1704)** Anti TCL1A; P14 TCL1; T cell leukemia 1; TCL1; TCL1 PEN; Tcl1a	WB, IHC-P, ICC/IF, FC	Human
	T Cell Leukemia/Lymphoma Protein 1A Antibody (YA1704) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1704), targeting T Cell Leukemia/Lymphoma Protein 1A, with a predicted molecular weight of 13 kDa (observed band size: 13 kDa). T Cell Leukemia/Lymphoma Protein 1A Antibody (YA1704) can be used for WB, IHC-P, ICC/IF, FC experiment in human background.

HY-P86267

	GCET2 Antibody (YA5959) GCSAM; GAL; GCET2; Germinal center-associated signaling and motility protein ; Germinal center B-cell-expressed transcript 2 protein; Germinal center-associated Lymphoma protein; hGAL;	IHC-P, ICC/IF/IF, ICC/IF, FC	Human
	GCET2 Antibody (YA5959) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GCET2. It can be applicated for IHC-P, ICC/IF/IF, ICC/IF, FC assays, in the background of human.

HY-P82647

	CBL Antibody (YA2392) CBL; CBL2; RNF55; E3 ubiquitin-protein ligase CBL; Casitas B-lineage Lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL	WB, ICC/IF, IP	Human
	CBL Antibody (YA2392) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2392), targeting CBL, with a predicted molecular weight of 100 kDa (observed band size: 120 kDa). CBL Antibody (YA2392) can be used for WB, ICC/IF, IP experiment in human background.

HY-P85077

	Cbl Antibody (YA4769) CBL; CBL2; RNF55; E3 ubiquitin-protein ligase CBL; Casitas B-lineage Lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Rat
	Cbl Antibody (YA4769) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Cbl. It can be applicated for WB, IHC-P, ICC/IF, FC, ELISA assays, in the background of human, mouse, rat.

HY-P81294

	Phospho-CBL (Tyr774) Antibody (YA1014) CBL; CBL2; RNF55; E3 ubiquitin-protein ligase CBL; Casitas B-lineage Lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL	WB, IP	Human, Rat
	Phospho-CBL (Tyr774) Antibody (YA1014) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1014), targeting Phospho-CBL (Tyr774), with a predicted molecular weight of 100 kDa (observed band size: 120 kDa). Phospho-CBL (Tyr774) Antibody (YA1014) can be used for WB, IP experiment in human, rat background.

HY-P81294A

	Phospho-CBL (Ser669) Antibody (YA1015) CBL; CBL2; RNF55; E3 ubiquitin-protein ligase CBL; Casitas B-lineage Lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL	WB	Human
	Phospho-CBL (Ser669) Antibody (YA1015) is a non-conjugated IgG antibody, targeting Phospho-CBL (Ser669), with a predicted molecular weight of 100 kDa (observed band size: 120 kDa). Phospho-CBL (Ser669) Antibody (YA1015) can be used for WB experiment in human background.

HY-P82361

	CXCR5 Antibody (YA2106) CXCR5; BLR1; MDR15; C-X-C chemokine receptor type 5; CXC-R5; CXCR-5; Burkitt Lymphoma receptor 1; Monocyte-derived receptor 15; MDR-15; CD185	WB, ICC/IF, FC	Human, Mouse, Rat
	CXCR5 Antibody (YA2106) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2106), targeting CXCR5, with a predicted molecular weight of 42 kDa (observed band size: 42 kDa). CXCR5 Antibody (YA2106) can be used for WB, ICC/IF, FC experiment in human, mouse, rat background.

HY-P80095

	Ctip2 Antibody (YA488) ATL1 alpha antibody; ATL1 antibody; ATL1 beta antibody; ATL1 gamma antibody; ATL1-delta antibody; B-cell CLL/Lymphoma 11B antibody; B-cell Lymphoma/leukemia 11B antibody; BC11B_HUMAN antibody; BCL-11B antibody; Bcl11b antibody; BCL11B/TRDC fusion antibody; COUP TF interacting protein 2 antibody; Ctip 2 antibody; CTIP-2 antibody; CTIP2 antibody; hRIT1 alpha antibody; hRit1 antibody; Radiation induced tumor suppressor gene 1 antibody; Rit 1 antibody; zinc finger protein hRit1 alpha antibody; ZNF856B antibody	WB, ICC/IF, IHC-P, FC	Human, Mouse
	Ctip2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 96 kDa, targeting to Ctip2. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Human, Mouse.

HY-P84973

	CD185 Antibody (YA4665) BLR1; MDR15; BLR 1 antibody; BLR1 antibody; Burkitt Lymphoma receptor 1 antibody; Burkitt Lymphoma receptor 1 GTP binding protein antibody; Burkitt Lymphoma receptor 1; GTP binding protein; chemokine; C-X-C motif; receptor 5; antibody; C X C chemokine receptor type 5 antibody; C-X-C chemokine receptor type 5 antibody; CD 185 antibody; CD185 antibody; CD185 antigen antibody; Chemokine; C-X-C motif; receptor 5 antibody; Chemokine C X C motif receptor 5 antibody; Chemokine CXC motif receptor 5 antibody; Chemokine receptor 5 antibody; CXC chemokine receptor type 5 antibody; CXC R5 antibody; CXC-R5 antibody; CXCR 5 antibody; CXCR-5 antibody; Cxcr5 antibody; CXCR5_HUMAN antibody; MDR 15 antibody; MDR-15 antibody; MDR15 antibody; MGC117347 antibody; Monocyte derived receptor 15 antibody; Monocyte-derived receptor 15 antibody
	CD185 Antibody (YA4665) is a non-conjugated antibody, targeting to CD185.

HY-P85022

	CD185 Antibody (YA4714) BLR1; MDR15; BLR 1 antibody; BLR1 antibody; Burkitt Lymphoma receptor 1 antibody; Burkitt Lymphoma receptor 1 GTP binding protein antibody; Burkitt Lymphoma receptor 1; GTP binding protein; chemokine; C-X-C motif; receptor 5; antibody; C X C chemokine receptor type 5 antibody; C-X-C chemokine receptor type 5 antibody; CD 185 antibody; CD185 antibody; CD185 antigen antibody; Chemokine; C-X-C motif; receptor 5 antibody; Chemokine C X C motif receptor 5 antibody; Chemokine CXC motif receptor 5 antibody; Chemokine receptor 5 antibody; CXC chemokine receptor type 5 antibody; CXC R5 antibody; CXC-R5 antibody; CXCR 5 antibody; CXCR-5 antibody; Cxcr5 antibody; CXCR5_HUMAN antibody; MDR 15 antibody; MDR-15 antibody; MDR15 antibody; MGC117347 antibody; Monocyte derived receptor 15 antibody; Monocyte-derived receptor 15 antibody	FC, ELISA	Human
	CD185 Antibody (YA4714) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD185. It can be applicated for FC, ELISA assays, in the background of human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-10446

Pralatrexate 5+ Cited Publications		Alkynes
Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a K_i of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-129602

SD-36 5+ Cited Publications		PROTAC Synthesis
SD-36 is a potent and efficacious STAT3 PROTAC degrader (K_d=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC₅₀=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase . SD-36 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-150251

SD-91 STAT3 degrader-2		PROTAC Synthesis
SD-91 (STAT3 degrader-2), a product of the hydrolysis of SD-36 (HY-129602), is a selective PROTAC-based STAT3 degrader with a K_i of 5.5 nM. SD-91 displays >300-fold selectivity over other STAT family protein members. SD-91 potently induces degradation of STAT3 protein in cells. SD-91 has anticancer effects, such as myeloid leukemia, lymphoma (Pink: ligand for target protein (HY-150895); Black: linker; Blue: E3 ligase ligand; E3 ligase ligand+linker: HY-176506) .

Cat. No.	Product Name		Classification

HY-153084

CD19 CAR mRNA (Mouse)		mRNA
CD19 CAR mRNA (Mouse) expresses mouse CD19 CAR protein. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia .

HY-132601A

Cobomarsen sodium MRG-106 sodium		Antisense Oligonucleotides
Cobomarsen sodium is an oligonucleotide inhibitor of miR-155. Cobomarsen sodium inhibits multiple gene pathways associated with cell survival (including JAK/STAT, MAPK/ERK and PI3K/AKT). Cobomarsen sodium can be used for the research of B-cell lymphoma .

HY-140739

DSPE-PEG2000-Maleimide 2 Publications Verification		Pegylated Lipids
DSPE-PEG2000-Maleimide is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration .

HY-153084A

CD19 CAR mRNA (Human) 1 Publications Verification		mRNA
CD19 CAR mRNA (Human) expresses Human CD19 CAR protein. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia .

HY-132601

Cobomarsen MRG-106		Antisense Oligonucleotides
Cobomarsen (MRG-106) is an oligonucleotide inhibitor of miR-155. Cobomarsen inhibits multiple gene pathways associated with cell survival (including JAK/STAT, MAPK/ERK and PI3K/AKT). Cobomarsen can be used for the research of B-cell lymphoma .

HY-161080

4'-Ethynyl-2'-deoxycytidine		Nucleosides and their Analogs C
4'-Ethynyl-2'-deoxycytidine is an anticancer nucleoside. 4'-Ethynyl-2'-deoxycytidine can used in study acute lymphoblastic leukemia and diffuse large B-cell lymphoma .

HY-W784565

5-Fluorouridine 5'-phosphate		Nucleotides and their Analogs U
5-Fluorouridine 5'-phosphate is an ODCase (orotidine-5′-monophosphate decarboxylase) inhibitor, with a K_i value of 98 µM for human ODCase and a K_i value of 645 µM for Methanobacterium ODCase. 5-Fluorouridine 5'-phosphate exhibits inhibitory activity against leukemia and lymphoma cell lines and can be used in cancer research .